95-95-95

Chasing 95-95-95: where Lindi stands

A mid-year review benchmarks Lindi against national targets — and names the populations still being missed.

AuthorPaulina Mlinga
Published19 Mar 2025
ProjectEpiC · Lindi
Read4 min
Field Dispatch
91-94-93
Lindi midline estimates
+6 pts
Suppression vs 2023
3,840
Active on ART
89%
On dolutegravir regimen
01

Where Lindi stands

The mid-2025 EpiC dashboard estimates Lindi region at 91-94-93 against the UNAIDS 95-95-95 targets — 91 percent of people living with HIV know their status, 94 percent of those who know their status are on treatment, and 93 percent of those on treatment are virally suppressed.

This is a six-percentage-point improvement on viral suppression versus the 2023 midline, achieved while active treatment cohorts grew by 14 percent.

02

What is driving the gains

Three operational shifts are visible in the data: the rollout of dolutegravir as the preferred first-line regimen (89 percent of clients now on a DTG-based regimen); the structured retention protocol for new initiates; and the routine viral load monitoring schedule held to the six-month target.

Each shift is small. Compounded, they move the cascade.

03

What remains

The remaining gap is concentrated in adolescents on ART and clients with high mobility between fishing landing sites. A dedicated cohort review is scheduled for Q4 2025 to design the next round of interventions for these two groups.

The third 95 is the hardest — because it cannot be bought with a campaign.
Key takeaway

Mid-2025 data shows Lindi closing in on the 95-95-95 targets, with viral suppression the remaining gap.

95-95-95LindiReview
Back to Field Journal